Navigation Links
Shire Delivers Strong 2012 Results and Reiterates Confidence in 2013
Date:2/14/2013

Non GAAP measure) at December 31, 2012 was $373 million (December 31, 2011: Non GAAP net debt of $488 million) including the impact of share purchases totalling $106 million under the share buy-back program.

  1. LDX, currently marketed as VYVANSE in the US and ELVANSE in certain territories in the EU for the treatment of ADHD.


OUTLOOK


We enter 2013 in a good position following our strong performance in 2012 and the investments we have made in previous years. We anticipate that our highly differentiated portfolio will deliver product sales growth in the low double digits.

We note the recent news of the approval of Barr's ANDA for ADDERALL XR. We derive insignificant income from our authorised generic supply contract with Barr (now owned by TEVA). We believe that branded ADDERALL XR can continue to compete successfully in a generic market as it has done over the last four years.

Royalties and other revenues are expected to be 30-40% lower than 2012. This reflects a full year's impact of the lower ADDERALL XR authorized generic royalty rate receivable from Impax, along with generic competition and patent expiry on other products, and the one-time $38 million of royalty income recorded in Q4 2012 following the resolution of the disagreement with GSK.

Our Non GAAP gross margin is expected to be at a similar level to 2012.

We expect high single digit growth in combined Non GAAP R&D and SG&A costs, with growth significantly weighted towards Non GAAP R&D as we continue to invest in our promising pipeline and progress our late stage clinical trials.

Our core effective tax rate on Non GAAP income is anticipated to remain in the range of 18-20%.

As we look forward to the year ahead, we expect our financial results to show further growth in line with current consensus earnings expectations for 2013(1).

  1. Based on the most recent consensus estimates
    '/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Regenerative Medicine and HealTogether Partner with Celebrity Chef Charles Mattocks to Raise Awareness of Diabetes and its Complications
2. NYSE Hot Stocks Earnings Forecast: Wells Fargo, Eli Lilly, Berkshire Hathaway, Coca-Cola, Valero Energy, and Altria Group
3. Shire Leads New Initiative to Reveal Challenges Facing Rare Disease Community
4. Dr Steven Gillis to Join Shire Board of Directors
5. Shire Second Quarter Product Sales Up 16%
6. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
7. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
8. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
9. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
10. Study Delivers Investment Benchmarks across Key New Product Launch Activities in Pharmaceutical Sector
11. SIS Delivers Advanced Interoperability With Siemens Soarian Clinicals To Improve Efficiency, Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
... Dec. 14, 2010 Samplify Systems, Inc., a ... the ultrasound market, is pleased to announce that ... has won Electronic Design Magazine,s Best ... category.  Details of Samplify,s AutoFocus™ beamforming technology currently ...
... 14, 2010 Pacira Pharmaceuticals, Inc. ... the New Drug Application (NDA) for EXPAREL™, a long-acting ... filing by the U.S. Food and Drug Administration (FDA). ... the initial indication of postsurgical analgesia by local administration. ...
Cached Medicine Technology:Samplify's AutoFocus™ Beamforming Technology Awarded Electronic Design's 'Best of 2010' 2
(Date:8/31/2015)... ... August 31, 2015 , ... GenHart Software, LLC, a rising player in ... small businesses operate as efficiently and cost effectively as possible, with a belief that ... their first year of operation – and the Charleston business community is taking notice. ...
(Date:8/30/2015)... , ... August 31, 2015 , ... Avid collector Andrew ... the Doors Shrine Auditorium concert posters. This hand colored artwork is one of the ... in Los Angles. Hawley states, "When the doors played the Shrine, the band ...
(Date:8/30/2015)... DE (PRWEB) , ... August 31, 2015 , ... ... exhibitor at the AHCA/NCAL 66th Annual Convention & Expo October 5th & 6th ... and organizations together, the AHCA/NCAL convention brings industry professionals from all over the ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... across platforms and devices, today announced it is a Silver Sponsor of the ... at Sky City Convention Centre in Auckland, NZ. Throughout the event, AvePoint will ...
(Date:8/30/2015)... ... ... Natural Rest contains a unique mixture of vitamins and herbs that are ... to improve mood disorders and anxiety. Like all other Creative Medical Health products, Natural ... regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one of ...
Breaking Medicine News(10 mins):Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2
... woman who comes to a health care centre does increase ... partners, a new study confirms. The study, led by ... at St. Michael,s Hospital, represents a major reversal of thinking ... or intimate partner violence. Until now, the research and ...
... around 2 billion dollars a year on remediation at ... used for groundwater monitoring. Yet according to Rolf Halden, ... information gathered is often of limited value. Under ... Department of Defense, Halden, assistant director at the Institute,s ...
... -- The sooner rehabilitation begins after knee replacement, the ... In the study, published March 7 in the ... than 150 patients who began rehabilitation within 24 hours ... of patients who began rehabilitation 48 to 72 hours ...
... , FRIDAY, March 4 (HealthDay News) -- In what experts ... have for the first time turned human embryonic stem cells ... of brain cell that,s lost to Alzheimer,s disease. The ... cholinergic" (BFC) neurons, is key to the progression of Alzheimer,s. ...
... Walter and Eliza Hall Institute have identified the key ... response. The finding could have wide-ranging repercussions for ... and change how the efficacy of newly developed drugs ... Erika Cretney, Dr Axel Kallies and Dr Stephen Nutt ...
... Sledding is the most common cause of injury among winter ... list of the top five injury-causing winter activities. "More ... States due to sledding. More than 30 percent are head ... specialist at Gottlieb Memorial Hospital in Melrose Park, Ill., part ...
Cached Medicine News:Health News:Universal screening programs can uncover abuse, study finds 2Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 2Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 3Health News:Scientists Use Stem Cells, Skin Cells to Create Brain Cells Lost to Alzheimer's 4Health News:Newly identified cell population key to immune response 2
Cold light source single outlet....
... The 4150S is a state ... halogen light source with an ... standard coupler to connect optical ... source distinguishes itself from all ...
The 9300XSP is the brightest light source available. Visualize more clearly, see color more accurately, and work more effectively. Luxtecs xenon lighting delivers bright, white light that is as close...
The Carl Zeiss Head-worn Loupes L and LC are the ideal solution if a low magnification suffices for your work and you want to keep your hands free to perform the task at hand....
Medicine Products: